Today's Clinical Lab - News, Editorial and Products for the Clinical Laboratory
Photo a long oval bacteria with small bacteriophages on its surface

New Highly Sensitive Lyme Disease Test Holds Promise

The new PCR-based test can distinguish between early- and late-stage Lyme disease

Photo portrait of Miriam Bergeret
Miriam Bergeret, MSc
Photo portrait of Miriam Bergeret

Miriam Bergeret, MSc, is Today's Clinical Lab's managing editor.

ViewFull Profile
Learn about ourEditorial Policies.
Published:Apr 14, 2021
|1 min read
Register for free to listen to this article
Listen with Speechify

Current tests for Lyme disease (LD) lack sensitivity during the early stages of disease and often cannot distinguish between different tick-borne diseases, but a new highly sensitive test promises to improve LD detection. The test was recently described in Frontiers in Microbiology

The most common disease transmitted by tick bite, LD is usually diagnosed based on clinical symptoms and a history of tick exposure. However, the symptoms don’t occur in every LD patient and are also largely indistinguishable from other tick-borne illnesses that require different treatments. The similarity between symptoms and lack of a diagnostic test that can accurately distinguish between infections often hinders correct diagnosis and treatment.

LD is difficult to detect in the early stages of disease when it is easier to treat as current PCR tests directly target LD-causing bacteria using DNA regions with a single copy in each bacterium. To overcome these challenges, researchers developed a new highly sensitive test that uses an internally controlled quantitative PCR to target a multicopy gene called terminase large subunit (terL) only present in prophages found in LD-causing bacteria.

The researchers evaluated the new test, known as Ter-qPCR, and found that it was able to detect the presence of a single bacterium in a 0.3 mL sample of blood, a sensitivity appropriate for clinical settings. Moreover, in a set of blood samples from healthy controls and LD patients, they found significant quantitative differences in the amount of terL in LD patients with early- versus late-stage disease, demonstrating the potential of using terL as an early marker of LD.

“Together, the data suggests that the prophage-targeting PCR has significant power to improve success detection for LD,” wrote the authors, who believe this technique could be applied to other diseases caused by bacteria that carry unique prophages.